Mead Johnson Nutrition Co., the US-based infant formula firm, today (28 April) booked falling first-quarter sales and earnings due to the impact of its IPO in February.
Go deeper with GlobalData
The company, which is listed non the New York stock exchange, reported a 1% fall in net sales to $693m for the three months to the end of March.
Mead Johnson, in which Bristol-Myers Squibb still owns an 85% stake, said net earnings attributable to the business totalled $103.5m, or $0.55 per diluted share – compared with $130.6m, or $0.77 per diluted share, a year earlier.
Stripping out the effects of the IPO, sales rose by 7% on a constant-currency basis thanks to a “strong performance” in Asia and Latin America.
Underlying net earnings increased by 2% to $115.8m, or $0.57 per diluted share, up from $113.5m, or $0.56 per diluted share, for the same quarter a year ago.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCEO Stephen Golsby said: “We expect our full-year results will be driven by double-digit revenue gains in our key growth markets in Asia and Latin America and supported by innovative new products scheduled for launch in the United States and internationally through the remainder of 2009.”
